TVRD Tvardi Therapeutics (TVRD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001346830
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
20
13F, latest reported quarter
Tvardi Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Tvardi Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
20 funds bought in last quarter
below 68% of Pharma & Biotech
Revenue
-66.0% year over year
below 84% of Pharma & Biotech
Margin
-255.2% net margin
below 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.9% of the float short (float per yahoo 2026-10-27) · 2.2 days to cover · settled 2026-10-15
below 60% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TVRD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.2%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TVRD: institutional holders (13F)
13F holdings, latest reported quarter
704,118 sh
$1.3M
344,382 sh
$654.3K
223,659 sh
$425.0K
111,133 sh
$211.2K
101,034 sh
$192.0K
Congress trades in TVRD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TVRD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TVRD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD RUSSELL 2000 VALUE INDEX FUND
$12.9K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$103.3K position · as of 2026-05-31
0.0%
ProShares Russell 2000 High Income ETF
$960 position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$170.7K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$4.7K position · as of 2026-05-31
0.0%
ProShares Ultra Russell2000
$744 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
0 active
1
Multi-phase
1 active
What changed recently
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanc
2026-10-23 · Completion moved 2027-02-01 → 2027-05-25
PHASE1,PHASE2
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor
2026-09-25 · Completion moved 2024-04-25 → 2024-05-06
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Christopherposner
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$4.7M
-$2.7M
$1.7M
-93%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 20 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TVRD financials
Revenue growth
-66.0%
XBRL, annual
Net margin
-255.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.6M
four quarters, 2024-04-01 to 2025-03-31
Revenue, TTM TVRD
| FY Dec 2025 | $7.6M |
| FY Dec 2024 | $7.1M |
| FY Dec 2023 | $21.0M |
| FY Dec 2022 | $41.9M |
| FY Dec 2021 | $23.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | $2.6M |
| Dec 2024 | $1.5M |
| Sep 2024 | $2.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-344.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TVRD
| FY Dec 2025 | -240.5% |
| FY Dec 2024 | -411.9% |
| FY Dec 2023 | -56.5% |
| FY Dec 2022 | -204.2% |
| FY Dec 2021 | -384.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -372.9% |
| Dec 2024 | -873.5% |
| Sep 2024 | -215.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$26.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TVRD
| FY Dec 2025 | -$24.5M |
| FY Dec 2024 | -$19.4M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$78.8M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$4.8M |
| Sep 2024 | -$6.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-126.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -24.5% |
| FY Dec 2022 | -44.3% |
| FY Dec 2021 | -37.1% |
| Jun 2026 | -126.2% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +1,615% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-85.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TVRD
| FY Dec 2025 | -54.1% |
| FY Dec 2024 | -36.5% |
| FY Dec 2023 | -7.7% |
| FY Dec 2022 | -39.8% |
| FY Dec 2021 | -34.1% |
| Jun 2026 | -85.1% |
| Mar 2026 | -47.7% |
| Dec 2025 | -54.1% |
| Sep 2025 | -52.3% |
| Jun 2025 | -40.7% |
| Mar 2025 | -53.9% |
| Dec 2024 | -36.5% |
| Sep 2024 | +69.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-131.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TVRD
| FY Dec 2025 | -116.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -93.8% |
| FY Dec 2022 | -45.1% |
| FY Dec 2021 | -37.0% |
| Jun 2026 | -131.2% |
| Mar 2026 | -112.6% |
| Dec 2025 | -116.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -112.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-226.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield TVRD
| FY Dec 2025 | -60.8% |
| FY Dec 2024 | -1.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -146.3% |
| Mar 2026 | -76.1% |
| Dec 2025 | -60.8% |
| Sep 2025 | -6.5% |
| Jun 2025 | -11.9% |
| Mar 2025 | +4.9% |
| Dec 2024 | -1.9% |
| Sep 2024 | -5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TVRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $7.1M | $21.0M | $41.9M |
| Operating income | -$26.7M | -$28.1M | -$121.5M | -$87.5M |
| Net income | -$18.2M | -$29.4M | -$11.8M | -$85.5M |
| EPS (diluted) | -3.26 | -11.42 | -26.26 | -19.12 |
| Operating cash flow | -$23.5M | -$18.3M | -$92.1M | -$78.7M |
| Cash | $20.7M | $31.6M | $51.8M | $63.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
TVRD Stock Sonar score 4/7 axes
Find similar shapesCompareTVRD ranks highest on institutional and government (32nd percentile) and risk and compliance (32nd), and lowest on growth (16th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
